Proteinuria immune response

Autoimmune-like phenomena in Brown Norway rats induced by mercuiy(II) chloride peak around day 10 after the last of five subcutaneous injections. After 20 days, immune alterations are mostly at control level, and the kidney effects (e.g. proteinuria) are clearly less than on day 10 (Aten et al., 1988). In addition, low-dose pretreatment of Brown Norway rats with mercuiy(II) chloride prevents development of adverse immunity (Szeto et al., 1999), and neonatal injection of mercury(II) chloride in Brown Norway rats renders them tolerant to mercury-induced (but not gold-induced) autoimmune phenomena (Field et al., 2000). These phenomena, transience of autoimmune effects as well as low-dose protection, are shown to be due at least in part to the development of regulatory immune cells. In the case of mercury(II) chloride, these cells have been identified as either IFN-y-producing CD8+CD45RC high regulatory T cells (Pelletier et al., 1990 Mathieson et al., 1991 Szeto et al., 1999 Field et al., 2003) or RT6.2+ T cells (Kosuda et al., 1994). In view of this, it is relevant to note that Lewis rats that produce predominantly CD8+ regulatory T cells ( suppressor T cells) in response to mercury(II) chloride are resistant to mercury-induced autoimmunity and instead display a polyclonal immunosuppressive response (Pelletier et al., 1987). Based on these differences in strain sensitivity, it is clear that susceptibility to mercury-induced autoimmune effects is dependent on MHC class II haplo-type (Aten et al., 1991). 

Table 13.1). Other more severe symptoms sometimes reported are bronchospasm, chest pain, seizures, and systemic anaphylaxis that may be life-threatening. Reactions to oxaliplatin are similar to those seen in response to cisplatin and carboplatin, but the responses to oxali-plafin tend to be more heterogeneous and unpredictable with fewer cutaneous reactions idiosyncratic reactions like cytokine release syndrome and pulmonary fibrosis fewer reports of severe anaphylaxis and a higher incidence of respiratory symptoms including laryngeal spasms and hypoxemia A few cases of type II thrombocytopenia and type HI immune complex-mediated urticaria, joint pain, and proteinuria associated with oxaliplatin have also been reported. 

---